ChIP-chip of wild_type and K14MycER in Mouse genome wide proximal promoter regions
Ontology highlight
ABSTRACT:
ORGANISM(S): Mus musculus
SUBMITTER: Elisabete Nascimento
PROVIDER: E-MTAB-555 | biostudies-arrayexpress |
REPOSITORIES: biostudies-arrayexpress
Similar Datasets
Project description:Expression analysis of a c-Myc knockin effects on gene expression in adult mouse skin. We used an inducible system to overexpress c-Myc specifically in adult mouse K14 positive keratinocytes and analysed the resulting changes in gene expression by means of microarrays.
2011-10-26 | E-MTAB-553 | biostudies-arrayexpress
Project description:Identification of c-Myc, H3K4me3 and a set of skin differentiation specific TFs binding sites in the genome of normal or c-Myc overexpressed mouse epidermis
2011-10-26 | E-MTAB-556 | biostudies-arrayexpress
Project description:Expression analysis of K14Sin3afl/flCreER,K14Mycfl/flCreER and K14Sin3aMycfl/flCreER effects on gene expression in adult mouse skin. We used a conditional knock out strategy to delete Sin3a and/or c-Myc specifically in adult mouse K14 positive keratinocytes and analysed the resulting changes in gene expression by means of microarrays.
2011-10-26 | E-MTAB-554 | biostudies-arrayexpress
Project description:Cutaneous squamous tumors rely on autocrine/paracrine loops for proper fitness. Targeting this Achilles’ heel is therefore considered a potential avenue for patient treatment. However, the mechanisms that engage and sustain such programs during tumor ontogeny are poorly understood. Here, we show that two Rho/Rac activators, the exchange factors Vav2 and Vav3, control the expression of an epithelial autocrine/paracrine program that regulates keratinocyte survival and proliferation as well as the creation of an inflammatory microenvironment. Vav proteins are also critically involved in some of the subsequent autocrine signaling loops activated in keratinocytes. The genetic inactivation of both Vav proteins reduces tumor multiplicity without hampering skin homeostasis, thus suggesting that pan-specific Vav therapies may be useful in skin tumor prevention and treatment. The dorsal skin of WT and DKO mice (Vav2-/-;Vav3-/-) were treated with either one or four applications of phorbol ester 12-O-tetradecanoylphorbol-13 acetate (TPA) (6.8 nmol in 200 μl acetone) two days after shaving. As control, we applied 200 μl of acetone. Animals were euthanized 24 hours after treatment.
2013-07-30 | E-GEOD-40849 | biostudies-arrayexpress
Project description:The experiment is a study of the effects of signal strength in the Ras pathway. In particular, we studied a gain-of-function mutant of Kras, KrasG12D. We generated these mutant mice and performed microarray analyses on RNA extracted from whole skin, comparing KrasG12D mice to wild-type mice, with three replicates of each.
2011-06-03 | E-MTAB-700 | biostudies-arrayexpress
Project description:T-ALL Xenograft Histone Modification at ERG locus: The cells used are human T-acute lymphoblastic leukaemia cells that have been propagated in NOD/SCID mice. T-ALL8,T-ALL16, T-ALL27, T-ALL29, T-ALL30 and T-ALL31 are cells from six different patients. Normalized data files containing chromosome 21 data are available on the FTP site for this experiment in the E-MTAB-431.additional.zip archive.
2012-01-01 | E-MTAB-431 | biostudies-arrayexpress
Project description:The transcription factor Myc is a critical regulator of diverse cellular processes, including both replication and apoptosis. However, differences in Myc-regulated gene expression responsible for such opposing outcomes in vivo remain obscure. To address this we have examined time-dependent changes in global gene expression in vivo in two distinct transgenic mouse models in which conditional Myc activation promotes distinct outcomes - tissue expansion in skin suprabasal keratinocytes (SBK) or involution in pancreatic islet beta cells. We utilised the MycERTAM transgenic mouse model, allowing activation of a chimeric Myc protein via daily treatment with 4 hydroxytamoxifen (4OHT). We compared the change in expression following MycERTAM activation at 4 time points (4hrs, 8hrs, 16hrs and 32hrs following 4OHT treatment) for the two tissues to identify genes whose expression profiles differ between the two.
2010-12-01 | E-MEXP-2952 | biostudies-arrayexpress
Project description:Analysis of technical variance of ChIP-on-Chip studies by characterization of Myc-binding in HL60 cells. Keywords: Chip-on-chip Characterization of c-Myc binding in HL60 cells. Thirteen biologically independent replicates of growing HL60 cells were subjected to ChIP with an N-terminal c-Myc antibody and hybridized to CpG island microarrays
2010-05-17 | E-GEOD-8447 | biostudies-arrayexpress
Project description:This SuperSeries is composed of the following subset Series:; GSE10726: Expression data from skin of epithelial activated beta-catenin mutant mouse embryo; GSE10727: Expression data from dermis of epithelial activated beta-catenin mutant mouse embryo; GSE10728: Expression data from epidermis of epithelial activated beta-catenin mutant mouse embryo Experiment Overall Design: Refer to individual Series
2008-06-20 | E-GEOD-10733 | biostudies-arrayexpress
Project description:Herein we demonstrate the efficacy of an unbiased proteomics screening approach for studying protein expression changes in the KC-Tie2 psoriasis mouse model, identifying multiple protein expression changes in the mouse and validating these changes in human psoriasis. KC-Tie2 mouse skin samples (n=3) were compared with littermate controls (n=3) using gel-based fractionation followed by label-free protein expression analysis. 5482 peptides mapping to 1281 proteins were identified and quantitated: 105 proteins exhibited fold-changes ≥2.0 including: stefin A1 (average fold change of 342.4 and an average P = 0.0082; cystatin A, human orthologue); slc25a5 (average fold change of 46.2 and an average P = 0.0318); serpinb3b (average fold change of 35.6 and an average P = 0.0345; serpinB1, human orthologue); and kallikrein related peptidase 6 (average fold change of 4.7 and an average P = 0.2474; KLK6). We independently confirmed mouse gene expression-based increases of selected genes including serpinb3b (17.4-fold, P < 0.0001), KLK6 (9.0-fold, P = 0.002), stefin A1 (7.3-fold; P < 0.001) and slc25A5 (1.5-fold; P = 0.05) using qRT-PCR on a second cohort of animals (n=8). Parallel LC/MS/MS analyses on these same samples verified protein-level increases of 1.3-fold (slc25a5; P < 0.05), 29,000-fold (stefinA1; P < 0.01), 322-fold (KLK6; P < 0.0001) between KC-Tie2 and control mice. To underscore the utility and translatability of our combined approach, we analyzed gene and protein expression levels in psoriasis patient skin and primary keratinocytes vs. healthy controls. Increases in gene expression for slc25a5 (1.8-fold), cystatin A (3.0-fold), KLK6 (5.8-fold) and serpinB1 (76-fold; all P < 0.05) were observed between healthy controls and involved lesional psoriasis skin and primary psoriasis keratinocytes. Moreover slc25a5, cystatin A, KLK6 and serpinB1 protein were all increased in lesional psoriasis skin compared to normal skin. These results highlight the usefulness of preclinical disease models using readily-available mouse skin and demonstrate the utility of proteomic approaches for identifying novel peptides/proteins that are differentially regulated in psoriasis that could serve as sources of auto-antigens or provide novel therapeutic targets for the development of new anti-psoriatic treatments.
2014-10-30 | PXD001387 | Pride